Survival and Prognostic Factors of Early Childhood Medulloblastoma: an International Meta-analysis
Overview
Authors
Affiliations
Purpose: To assess the prognostic role of clinical parameters and histology in early childhood medulloblastoma.
Patients And Methods: Clinical and histologic data from 270 children younger than age 5 years diagnosed with medulloblastoma between March 1987 and July 2004 and treated within prospective trials of five national study groups were centrally analyzed.
Results: Two hundred sixty children with medulloblastoma and specified histologic subtype were eligible for analysis (median age, 1.89 years; median follow-up, 8.0 years). Rates for 8-year event-free survival (EFS) and overall survival (OS) were 55% and 76%, respectively, in 108 children with desmoplastic/nodular medulloblastoma (DNMB) or medulloblastoma with extensive nodularity (MBEN); 27% and 42%, respectively, in 145 children with classic medulloblastoma (CMB); and 14% and 14%, respectively, in seven children with large-cell/anaplastic (LC/A) medulloblastoma (P < .001). Histology (DNMB/MBEN: hazard ratio [HR], 0.44; 95% CI, 0.31 to 0.64; LC/A medulloblastoma: HR, 2.27; 95% CI, 0.95 to 5.54; P < .001 compared with CMB), incomplete resection and metastases (M0R1: HR, 1.86; 95% CI, 1.29 to 2.80; M+: HR, 2.28; 95% CI, 1.50 to 3.46; P < .001 compared with M0R0), and national group were independent prognostic factors for EFS, and OS. The HRs for OS ranged from 0.14 for localized M0 and DNMB/MBEN to 13.67 for metastatic LC/A medulloblastoma in different national groups.
Conclusion: Our results confirm the high frequency of desmoplastic variants of medulloblastomas in early childhood and histopathology as a strong independent prognostic factor. A controlled de-escalation of treatment may be appropriate for young children with DNMB and MBEN in future clinical trials.
Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179.
Li Y, Lim C, Dismuke T, Malawsky D, Oasa S, Bruce Z Nat Commun. 2025; 16(1):1091.
PMID: 39904981 PMC: 11794477. DOI: 10.1038/s41467-024-54861-3.
Pionelli M, Mazio F, Errico M, Russo C, Cristofano A, Covelli E Front Oncol. 2024; 14:1386468.
PMID: 39540155 PMC: 11557518. DOI: 10.3389/fonc.2024.1386468.
Tsiami F, Lago C, Pozza N, Piccioni F, Zhao X, Lulsberg F Acta Neuropathol Commun. 2024; 12(1):125.
PMID: 39107797 PMC: 11304869. DOI: 10.1186/s40478-024-01831-x.
Salceda-Rivera V, Tejocote-Romero I, Osorio D, Bellido-Magana R, Lopez-Facundo A, Anaya-Aguirre S Front Oncol. 2024; 14:1376574.
PMID: 38756654 PMC: 11096484. DOI: 10.3389/fonc.2024.1376574.
New CNS tumor classification: The importance in pediatric neurosurgical practice.
Del Rio R, Cicutti S, Moreira D, Gonzalez Ramos J Surg Neurol Int. 2024; 15:130.
PMID: 38742003 PMC: 11090558. DOI: 10.25259/SNI_681_2023.